Biotech entity
Coverage clusters in pharma, which accounts for 5 of those 6, with the remainder spread across 1 other category. Sentiment skews more negative than the wider beat, at 67% negative against 18% across all 529 Biotech stories in the same window.
Last mentioned: 1d ago
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 67 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Coverage clusters in pharma, which accounts for 5 of those 6, with the remainder spread across 1 other category. Sentiment skews more negative than the wider beat, at 67% negative against 18% across all 529 Biotech stories in the same window. Of the tracked stories, 2 of 6 also mention FDA, the most common co-covered peer. The 181-day window averages about 0.2 stories each week. The busiest single day carried 2. Their average consequence score of 7 runs above the beat's 6.1 for that window. They are less corroborated than the beat average, carrying 3 original sources each against 3.5 for the same window. This profile follows 6 Biotech stories mentioning mifepristone across the period from March 13, 2026 to September 9, 2026.
Computed from the 6 stories linked to this entity, with beat comparisons drawn from all 529 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering mifepristone. Shared-story counts are live from our verified record — not editorial picks.
5th Circuit hears mifepristone arguments
Louisiana AG Liz Murrill and Rosalie Markezich argue for tighter prescribing rules before a three-judge panel in New Orleans.
Media Backlash
Health experts and advocacy groups label the bill's scientific claims regarding water pollution as unverified.
Bill Introduction
Rep. Mary Miller introduces the Clean Water For All Life Act in the House.
Press Conference
Miller and Kristan Hawkins (Students for Life) present the bill as an environmental protection measure.
Law Signed
Governor signs the law, enabling the Department of Corrections to begin distribution to providers.
Legislation Passed
Washington legislature passes bill to clarify state distribution authority.
Missouri Pause Request
DOJ files a request in federal court to pause the Missouri-led lawsuit citing an ongoing FDA review.
Hawley Federal Bill
Senator Josh Hawley introduces a bill in the Senate to ban mifepristone nationwide.
Louisiana Pause Request
DOJ asks Louisiana to pause its separate lawsuit; request is rejected by AG Liz Murrill.
Missouri Lawsuit Filed
Missouri, Kansas, and Idaho file suit against the FDA to restrict mifepristone access.
Louisiana pill access estimated at 770–900 monthly
A Society for Family Planning survey estimates that 770–900 Louisiana women per month obtained abortion pills from out-of-state providers under shield laws.
SCOTUS Ruling
Supreme Court preserves access to mifepristone on standing grounds, but litigation continues.
SCOTUS Ruling
Supreme Court preserves access to mifepristone by ruling plaintiffs lacked standing in FDA challenge.
Initial Stockpile Purchase
Governor Inslee orders 30,000 doses of mifepristone following a Texas court ruling.
Supreme Court allows states to decide abortion issue
The Dobbs decision clears the path for state abortion bans and sets up the current legal battles over cross-border medication abortion.
Dobbs Decision
SCOTUS overturns Roe v. Wade, triggering state-level bans and increasing demand for pills.
Telehealth Shift
FDA permanently removes the requirement that mifepristone be dispensed in person.
Label Update
FDA expands usage to 70 days gestation and reduces required office visits.
FDA Approval
FDA approves Mifeprex (mifepristone) for medical termination of pregnancy.
For biopharma, the dispute over mifepristone prescribing rules is a test of FDA regulatory authority over an approved drug's risk evaluation and mitigation strategy. The case may influence how drug safety restrictions are litigated and how federal preemption applies to medication abortion.
Source: MedPage Today · chicagotribune.com
Medication abortion has surged to account for the majority of pregnancy terminations in the U.S., driven by telehealth expansion and mail-order access. This shift has catalyzed a sophisticated legal and legislative counter-offensive aimed at the FDA's regulatory authority and the distribution of pharmaceutical products.
A Georgia woman has been charged with murder after allegedly using medication to induce an abortion, marking a significant escalation in the criminalization of self-managed reproductive care. This case highlights the growing legal and regulatory volatility surrounding the distribution and use of FDA-approved abortion pills in restrictive jurisdictions.
Source: abc15.com · citizensvoice.com
House Republicans have introduced the Clean Water For All Life Act, a bill that seeks to restrict abortion pill access by framing fetal remains as environmental pollutants. The legislation would mandate 'catch kits' for patients, ban telehealth prescriptions, and impose severe criminal penalties including five-year prison sentences.
Washington Governor has signed legislation authorizing the state to distribute its 30,000-dose stockpile of mifepristone to private and non-profit healthcare providers. The law resolves previous licensing hurdles that prevented the state's Department of Corrections from acting as a wholesale distributor for reproductive health medications.
The Department of Justice has requested a federal court to pause a multi-state lawsuit against the FDA regarding the abortion pill mifepristone. The move suggests a strategic effort to allow the FDA to conduct its own internal review of the drug's safety and distribution protocols.
mifepristone is linked from 6 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
